Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Pharmacy Guide
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Methocarbamol neuraxpharm 750 mg film-coated tablets
⚠ This medicine appears to have been discontinued
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Methocarbamol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
What it is and what it is used for
for
The name of your medicine is Methocarbamol 750 mg film-coated tablets, referred to as Methocarbamol tablets throughout this leaflet. Methocarbamol tablets contain methocarbamol, an active substance used to treat muscle tension. Methocarbamol is used for the symptomatic treatment of painful muscular tension, especially in the lower back (lumbago). Methocarbamol tablets are used in adults. 2.
What you need to know before you take it
e Methocarbamol tablets
Do not take Methocarbamol tablets if you are allergic to methocarbamol or any of the other ingredients of this medicine (listed in section 6) in the event of comatose or pre-comatose states if you suffer from disorders of the central nervous system if you suffer from pathological muscle weakness (myasthenia gravis) if you tend to have epilepsy Warnings and precautions Talk to your doctor or pharmacist before taking Methocarbamol tablets: if you suffer from impaired kidney and / or liver function if you are having any medical investigations or tests as methocarbamol could interfere with the results. Tell your doctor that you are taking methocarbamol before you have the test. Children and adolescents This medicine is not intended for use in children and adolescents, as safety and efficacy in these patient groups have not been established. Other medicines and Methocarbamol tablets Tell your doctor or pharmacist if you are taking/ using, have recently taken/ used or might take/ use any other medicines. The concomitant administration of methocarbamol and centrally acting medicines such as barbiturates, opiate derivatives and appetite suppressants may potentiate the effects of the medicines.
Methocarbamol can potentiate the effect of anticholinergic medicines such as atropine and some psychotropic medicines. Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore methocarbamol must not be administered to patients with pathological muscle weakness (myasthenia gravis) receiving pyridostigmine. Methocarbamol tablets with alcohol Using methocarbamol together with alcohol may potentiate the effect of the medicine. Do not drink alcohol while you are taking methocarbamol. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy If you are pregnant, you should not take Methocarbamol tablets, since the safe use of methocarbamol during pregnancy has not been established. Breast-feeding It is not known whether methocarbamol and/or its metabolites are excreted into human milk. Therefore, you should not take Methocarbamol tablets if you are breast-feeding. Driving and using machines Methocarbamol may affect your ability to drive and use machines. Methocarbamol may make you feel sleepy and may affect your ability to drive, operate machinery and carry out other hazardous activities. Before you consider driving a vehicle or using machines, you should take account of your state of health and the possible side effects of methocarbamol. You should therefore refrain from these activities until you have sufficient experience to know that you will not suffer any side effects. Information about some of the ingredients of this medicine Methocarbamol tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'. 3.
How to take it
Methocarbamol tablets
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Adults Unless otherwise prescribed by your doctor, the usual dose for adults is 1500 mg methocarbamol (2 film-coated tablets) 3 times a day. At the beginning of the treatment a dose of 1500 mg methocarbamol (2 film-coated tablets) 4 times a day is recommended. In severe cases up to 7500 mg methocarbamol (10 film-coated tablets) per day can be taken. Elderly Elderly patients may only need half the usual dose to give the same relief from the pain and muscle spasms. Liver impairment You may need a longer interval between taking the tablets if you have liver disease. You should always follow your doctor's instructions carefully. Method of administration Methocarbamol tablets are for oral use. Take the tablets with sufficient water. The score line is only there to help you break the tablet if you have difficulties in swallowing it whole and not to divide the tablet into equal doses. The duration of treatment depends on the symptoms induced by muscle tension, but should not exceed 30 days. If you take more Methocarbamol tablets than you should
Inform your doctor who will decide what measures to take. If you forget to take Methocarbamol tablets If you forget to take a dose, simply take the next dose when it is due. Do not take a double dose to make up for the forgotten dose. If you stop taking Methocarbamol tablets Please inform your doctor if you intend to discontinue the treatment with Methocarbamol. Special effects of discontinuation of the medicine are not to be expected. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Rare (may affect up to 1 in 1,000 people) Reddening of the eyes (conjunctivitis) with nasal congestion Headache, vertigo, metallic taste Low blood pressure Angioneurotic oedema Itching, skin rash, urticaria, fever Very rare (may affect up to 1 in 10,000 people) Shock reaction Loss of appetite Unrest, anxiety, confusion Fainting, involuntary eye movement, dizziness, tremor, convulsion Impaired vision Slow heartbeat Hot flushes Nausea, vomiting Not known (frequency cannot be estimated from the available data) Drowsiness Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. 5.
How to store it
Methocarbamol tablets
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the blister after "EXP". The expiry date refers to the last day of that month.
PVC/ACLAR//Al blisters This medicine does not require any special storage conditions. Polyvinylchloride (PVC)/ aluminium blister Do not store above 30oC. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.
Contents of the pack and other information
What Methocarbamol 750 mg tablets contain The active substance is methocarbamol. Each film-coated tablet contains 750 mg methocarbamol. The other ingredients are: Tablet core: lactose monohydrate, croscarmellose sodium, sodium lauryl sulfate, povidone, colloidal anhydrous silica, magnesium stearate. Film-coating: polyvinyl alcohol, titanium dioxide (E 171), talc, macrogol 3350. What Methocarbamol 750 mg film-coated tablets look like and contents of the pack White, oblong, biconvex, film-coated tablets with score line on one side, size: approx. 19 x 8 mm. The score line is only there to help you break the tablet if you have difficulties in swallowing it whole and not to divide the tablet into equal doses. Methocarbamol 750 mg film-coated tablets are available in packs of 20, 50 and 100 film-coated tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder Neuraxpharm UK Limited First Floor, Building 1410, Arlington Business Park, Theale, Reading, Berkshire, RG7 4SA United Kingdom Manufacturer Neuraxpharm Pharmaceuticals, S.L. Avda. Barcelona 69 08970 Sant Joan Despí Barcelona Spain or neuraxpharm Arzneimittel GmbH Elisabeth-Selbert-Str.23 40764 Langenfeld Germany This leaflet was last revised in March 2026
Frequently asked questions about Methocarbamol neuraxpharm 750 mg film-coated tablets
How do I take Methocarbamol neuraxpharm 750 mg film-coated tablets?
Methocarbamol neuraxpharm 750 mg film-coated tablets comes as tablet containing 750mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
What is the active substance in Methocarbamol neuraxpharm 750 mg film-coated tablets?
The active substance in Methocarbamol neuraxpharm 750 mg film-coated tablets is methocarbamol.
Are there equivalent medicines to Methocarbamol neuraxpharm 750 mg film-coated tablets?
Medicines with the same active substance, strength and form include: Robaxin-750, 750 mg Film-coated Tablets, Methocarbamol 750 mg film coated-Tablet, Methocarbamol 750 mg film-coated tablets. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
Where does this information come from?
This leaflet reproduces the patient information leaflet approved for Methocarbamol neuraxpharm 750 mg film-coated tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Can I get Methocarbamol neuraxpharm 750 mg film-coated tablets without a prescription?
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
About this leaflet
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
- Source: electronic medicines compendium (emc), Datapharm
- Active substance: methocarbamol
- Official document: view the original leaflet on emc →
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
4.1. Therapeutic indications
Symptomatic treatment of painful muscle tension, in particular low back pain (lumbago).
Methocarbamol is indicated in adults.
4.2. Posology and method of administration
Posology
Adults
The recommended dose for adults is 1500 mg methocarbamol 3 times a day. At the beginning of treatment a dose of 1500 mg methocarbamol 4 times a day is recommended.
In severe cases up to 7500 mg methocarbamol per day can be taken.
The duration of treatment depends on the symptoms induced by muscle tension, but should not exceed 30 days.
Paediatric population
The safety and efficacy of Methocarbamol in children and adolescents have not been established.
Elderly patients
Half the maximum dose or less may be sufficient to produce a therapeutic response.
Patients with hepatic impairment
In patients with chronic hepatic disease the elimination half-life may be prolonged. Therefore, consideration should be given to increasing the dose interval.
Method of administration
Methocarbamol is for oral use.
The film-coated tablets should be taken with sufficient water.
4.3. Contraindications
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Comatose or pre-comatose states
- Disorders of the central nervous system (CNS)
- Myasthenia gravis
- Epilepsy
4.4. Special warnings and precautions for use
Methocarbamol should be used with caution in patients with impaired renal and/or hepatic function.
Patients should be advised that the intake of alcohol during the treatment with methocarbamol or a combination with other centrally acting agents can lead to an increase in effects.
Methocarbamol tablets contain lactose
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Methocarbamol tablets contain sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 'sodium-free'.
Interference with laboratory tests
Methocarbamol may cause colour interference in screening tests for hydroxyindolacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
4.5. Interaction with other medicinal products and other forms of interaction
The concomitant administration of methocarbamol and centrally acting medicinal products such as barbiturates, opioids and appetite suppressants may mutually potentiate the effects of the medicinal products.
Methocarbamol can potentiate the effect of anticholinergic medicinal products such as atropine and some psychotropic medicinal products.
Using methocarbamol together with alcohol may potentiate the effect of the medicinal product.
Methocarbamol may inhibit the effect of pyridostigmine bromide. Therefore methocarbamol must not be administered to patients with myasthenia gravis receiving pyridostigmine.
4.6. Fertility, pregnancy and lactation
Pregnancy
There is no experience in the use of methocarbamol during pregnancy. Animal studies have not established safe use of methocarbamol with regard to effects upon pregnancy, embryonic/foetal development, parturition and postnatal development (see section 5.3). The potential risk for humans is not known. Therefore, methocarbamol should not be used during pregnancy.
Breast-feeding
It is not known whether methocarbamol and/or its metabolites pass into human milk. Methocarbamol and/or its metabolites are excreted into the milk of lactating dogs. Therefore methocarbamol should not be used by breast-feeding women.
Fertility
Animal reproductive studies have not been conducted with methocarbamol.
4.7. Effects on ability to drive and use machines
Methocarbamol has moderate influence on the ability to drive and use machines as methocarbamol may cause dizziness or drowsiness, especially if other medications capable of causing drowsiness are also being taken. Possible undesirable effects of methocarbamol may affect the patient's ability to drive and use machines.
4.8. Undesirable effects
The following undesirable effects were reported in connection with the use of methocarbamol. The frequency of possible undesirable effects - if relevant data are given in literature - is defined using the following conventions:
Very common (≥ 1/10)
Common (≥ 1/100 to < 1/10)
Uncommon (≥ 1/1,000 to < 1/100)
Rare (≥ 1/10,000 to < 1/1,000)
Very rare (≥ 1/10,000)
Not known (frequency cannot be estimated from the available data)
Infections and infestations
Rare
Conjunctivitis
Immune system disorders
Very rare
Anaphylactic reaction
Metabolic and nutrition disorders
Very rare
Anorexia
Psychiatric disorders
Very rare
Unrest, anxiety, confusion
Nervous system disorders
Rare
Headache, vertigo, metallic taste
Very rare
Syncope, nystagmus, dizziness, tremor, convulsion
Not known
Drowsiness
Eye disorders
Very rare
Impaired vision
Cardiac disorders
Very rare
Bradycardia
Vascular disorders
Rare
Hypotension
Very rare
Hot flushes
Respiratory, thoracic and mediastinal disorders
Rare
Nasal congestion
Gastrointestinal disorders
Very rare
Nausea, vomiting
Skin and subcutaneous tissue disorders
Rare
Angioneurotic oedema, itching, skin rash, urticaria
General disorders and administration site conditions
Rare
Fever
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9. Overdose
Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures and coma.
After oral intake of 22.5 to 50 g methocarbamol with suicidal intent two patients showed drowsiness, but recovered completely within 24 hours.
In literature 3 fatal cases are mentioned when patients in addition to methocarbamol consumed large quantities of alcohol (2 cases) or took opiates (1 case) with suicidal intent.
Management of overdose includes gastric lavage, symptomatic therapy and monitoring of vital functions. The usefulness of haemodialysis in managing overdose has not been established.
💬 Ask about this leaflet
Ask anything about Methocarbamol neuraxpharm 750 mg film-coated tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.